Itolerance Inc. and Kadimastem Ltd. have submitted a meeting request to the FDA's INTERACT committee for ITOL-102, which is under development as a potential cure for type 1 diabetes without the need for chronic immunosuppression.
Invios GmbH and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate Invios' immune-activating small molecule, INV-501, as a potential treatment for glioblastoma.
KLRG1 is expressed on a subset of T and NK cells, with KLRG1+CD8+ T cells having demonstrated strong antitumor cytotoxicity by releasing IFN-γ and TNF-α.
Abbisko Therapeutics Co. Ltd. has received clearance from China's National Medical Products Administration (NMPA) to conduct clinical trials in China of ABSK-051, a novel small-molecule CD73 inhibitor, for advanced solid tumors.
Researchers from Chugai Pharmaceutical Co. Ltd. presented preclinical data of SAIL-66, a trispecific antibody targeting Claudin-6 (CLDN6), CD137 (4-1BB) and CD3, for cancer immunotherapy.
Researchers from Arcturus Therapeutics Inc. and affiliated organizations presented preclinical data for LUNAR-CFTR, a novel mutation-agnostic, aerosolized CFTR replacement therapy for the treatment of cystic fibrosis (CF).
Bit Bio Ltd. (dba Bit.bio) has disclosed its cell therapy pipeline and a lead cell therapy candidate, bbHEP01, which is targeted to enter the clinic in 2025.
Researchers from Umoja Biopharma Inc. presented the discovery and preclinical evaluation of UB-VV200, a third-generation lentiviral vector containing a multi-domain fusion (MDF) protein consisting of a T cell-targeting anti-CD3 scFv and costimulatory proteins.
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor involved in tumor initiation, progression, and metastasis whose endogenous ligands are highly expressed in the tumor microenvironment of aggressive tumors.
Investigators at the Chinese Academy of Sciences have generated a chimeric monkey by injecting an embryonic stem cell into the morula, which is an extremely early embryo consisting of 16 to 32 cells. The animal survived for only 10 days, and it is not the first live birth of a chimeric primate. But it is the first such chimera with contributions from an embryonic stem cell, and that stem cell contributed a far higher proportion of cells in the newborn than have been achieved in previous attempts at creating chimeras.
RSS
